

# **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mr. JASTWANT SINGH

**AGE/ GENDER** : 55 YRS/MALE **PATIENT ID** : 1631006

**COLLECTED BY** :042410010002 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 01/Oct/2024 12:16 PM BARCODE NO. : A0465651 **COLLECTION DATE** : 01/Oct/2024 03:21PM CLIENT CODE. : KOS DIAGNOSTIC SHAHBAD REPORTING DATE : 01/Oct/2024 03:55PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit **Biological Reference interval** 

## **HAEMATOLOGY HAEMOGLOBIN (HB)**

16.5 HAEMOGLOBIN (HB) qm/dL 12.0 - 17.0

by CALORIMETRIC

### **INTERPRETATION:-**

Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the bodys tissues and returns carbon dioxide from the tissues back to the lungs.
A low hemoglobin level is referred to as ANEMIA or low red blood count.

### **ANEMIA (DECRESED HAEMOGLOBIN):**

- 1) Loss of blood (traumatic injury, surgery, bleeding, colon cancer or stomach ulcer)
- 2) Nutritional deficiency (iron, vitamin B12, folate)
- 3) Bone marrow problems (replacement of bone marrow by cancer)
- 4) Suppression by red blood cell synthesis by chemotherapy drugs
- 5) Kidney failure
- 6) Abnormal hemoglobin structure (sickle cell anemia or thalassemia). POLYCYTHEMIA (INCREASED HAEMOGLOBIN):

- 1) People in higher altitudes (Physiological)
- 2) Smoking (Secondary Polycythemia)
- 3) Dehydration produces a falsely rise in hemoglobin due to increased haemoconcentration
- 4) Advanced lung disease (for example, emphysema)
- 5) Certain tumors
- 6) A disorder of the bone marrow known as polycythemia rubra vera,
- 7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana



# **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. JASTWANT SINGH

**AGE/ GENDER** : 55 YRS/MALE **PATIENT ID** : 1631006

COLLECTED BY : REG. NO./LAB NO. : 042410010002

 REFERRED BY
 :
 REGISTRATION DATE
 : 01/Oct/2024 12:16 PM

 BARCODE NO.
 : A0465650
 COLLECTION DATE
 : 01/Oct/2024 03:21PM

 CLIENT CODE.
 : KOS DIAGNOSTIC SHAHBAD
 REPORTING DATE
 : 01/Oct/2024 04:34PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

### **CLINICAL CHEMISTRY/BIOCHEMISTRY**

LIPID PROFILE: BASIC

CHOLESTEROL TOTAL: SERUM 209.48<sup>H</sup> mg/dL OPTIMAL: < 200.0

by CHOLESTEROL OXIDASE PAP

BORDERLINE HIGH: 200.0 - 239.0

HIGH CHOLESTEROL: > OR = 240.0

TRIGLYCERIDES: SERUM 350.01<sup>H</sup> mg/dL OPTIMAL: < 150.0

by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

BORDERLINE HIGH: 150.0 - 199.0

HIGH: 200.0 - 499.0

VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM 42.16 mg/dL LOW HDL: < 30.0

by SELECTIVE INHIBITION

BORDERI INF HIG

BORDERLINE HIGH HDL: 30.0 -

60.0

DL CHOLESTEROL: SERUIVI 97.32 mg/aL OPTIMAL: < 100.0
by CALCULATED, SPECTROPHOTOMETRY ARONF OPTIMAL: 100.0

ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 - 159.0

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM 167.32<sup>H</sup> mg/dL OPTIMAL: < 130.0

by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 130.0 - 159.0

**BORDERLINE HIGH: 160.0 - 189.0** 

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

VLDL CHOLESTEROL: SERUM 70<sup>H</sup> mg/dL 0.00 - 45.00

by CALCULATED, SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM

768 97<sup>H</sup>

mg/dL

350.00 - 700.00

TOTAL LIPIDS: SERUM 768.97<sup>H</sup> mg/dL 350.00 - 700.00 by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM
by CALCULATED, SPECTROPHOTOMETRY

4.97<sup>H</sup>
RATIO
LOW RISK: 3.30 - 4.40
AVERAGE RISK: 4.50 - 7.0

MODERATE RISK: 7.10 - 11.0

LDL/HDL RATIO: SERUM 2.31 RATIO LOW RISK: 0.50 - 3.0

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MRRS. MD (PATHOLOGY)





CLIENT CODE.

## **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mr. JASTWANT SINGH

AGE/ GENDER : 55 YRS/MALE **PATIENT ID** : 1631006

**COLLECTED BY** REG. NO./LAB NO. :042410010002

REFERRED BY **REGISTRATION DATE** : 01/Oct/2024 12:16 PM BARCODE NO. **COLLECTION DATE** : 01/Oct/2024 03:21PM : A0465650

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

: KOS DIAGNOSTIC SHAHBAD

**Test Name** Value Unit **Biological Reference interval** by CALCULATED, SPECTROPHOTOMETRY MODERATE RISK: 3.10 - 6.0

REPORTING DATE

HIGH RISK: > 6.0

TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED. SPECTROPHOTOMETRY INTERPRETATION:

8.3<sup>H</sup>

**RATIO** 

3.00 - 5.00

: 01/Oct/2024 04:34PM

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

**End Of Report** 



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana

0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com